The global COVID-19 pandemic has been a great test of our infrastructure for rapid development of vaccines and biotherapeutics. Indeed, science delivered, and life-saving vaccines were approved for clinical use within a year. Since then, a range of treatments, including antibody-based drugs, have helped reduce the burden of COVID-19 disease.
However, new variants of SARS-CoV-1 and the surprising emergence of Monkeypox infections worldwide are a reminder that we need to keep developing new, more efficient ways to study and combat infectious diseases. In our new on-demand webinar “ subject matter experts Dr. David Apiyo and Allan Schell explain how information-rich, high-throughput 싸토리우스 technologies are helping pharmaceutical companies respond to current and emerging pathogens.
This webinar was part of the with SelectScience in May 2022.
Complete the Form to Watch Now
David is a Senior Manager, Applications at 싸토리우스, where he leads a team of Applications Managers focused on the Octet platforms and applications.
David began as a Field Applications Scientist in 2011 and transitioned to the marketing applications team in 2015. Prior to this, David worked as a Senior Development Scientist at Beckman Coulter. David obtained his Ph.D. in Protein Chemistry from Tulane University, New Orleans.
Allan SchellField 어플리케이션 Scientist ManagerSartorius
Allan Schell earned a MS in Toxicology from Colorado State University in 2010 and joined 싸토리우스 in 2016 as a FAS supporting the iQue product line. He has over 10 years of experience as an FAS supporting 유세포분석 applications and has been a manager of the applications team for 싸토리우스 FAS for over 3 years.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.